Oral fruquintinib combined with tegafur-gimeracil-oteracil potassium for advanced colorectal cancer to obtain longer progression-free survival: A case report

doi:10.4251/wjgo.v15.i5.902

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 5

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2473)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series.

Item

Count

PDF

133

WORD

HTML

1518

Figures (1-3)

215

Sum=1902

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

163

Download

408

Sum=571

May 15, 2023 (publication date) through Nov 18, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Gastrointest Oncol. May 15, 2023; 15(5): 902-910
Published online May 15, 2023. doi: 10.4251/wjgo.v15.i5.902

Full Size Figure Download Figure

Figure 2 Chest computed tomography before and after treatment with fruquintinib plus tegafur-gimeracil-oteracil potassium showed multiple metastases in both lungs. A-C: Computed tomography (CT) before fruquintinib plus tegafur-gimeracil-oteracil potassium (S-1) treatment (August 31, 2021); D-F: CT after fruquintinib plus S-1 treatment was given for 2 mo (November 1, 2021); G-I: CT after fruquintinib plus S-1 treatment was given for 10 mo (June 13, 2022); J-L: CT after fruquintinib plus S-1 treatment was given for 13.5 mo (October 12, 2022).

Citation: Qu FJ, Wu S, Kong Y. Oral fruquintinib combined with tegafur-gimeracil-oteracil potassium for advanced colorectal cancer to obtain longer progression-free survival: A case report. World J Gastrointest Oncol 2023; 15(5): 902-910
URL: https://www.wjgnet.com/1948-5204/full/v15/i5/902.htm
DOI: https://dx.doi.org/10.4251/wjgo.v15.i5.902